INTRODUCTION
Cisplatin is one of the most widely used anticancer drugs, being effective against a range of tumors including ovarian, genitourinary, lung, head and neck cancers (1) . Most noteworthy is the cure rate of testicular cancer, which has increased dramatically following the introduction of cisplatin-based chemotherapy (2) . Cisplatin and its second generation analogues carboplatin and oxaliplatin bind to DNA preferentially at the N7 position of guanine bases (1, 3, 4) , inhibiting replication (5, 6) and transcription (7) (8) (9) . The inhibition of those critical DNA-related processes triggers subsequent intracellular events that activate necrotic and apoptotic pathways (10). Despite its outstanding antitumor activity, cisplatin chemotherapy is limited by intrinsic and acquired resistance of certain tumors (11) . Several major mechanisms of cisplatin resistance have been discovered (12, 13) , and there have been numerous attempts to overcome the problems based on these mechanisms. One strategy has been to develop analogs of cisplatin with different antitumor profiles, like carboplatin and oxaliplatin (14, 15) . Another is to identify intracellular factors that participate in the mechanisms of cisplatin resistance, and to discover ways to control these factors.
HMGB1 is a highly abundant and ubiquitously expressed nuclear protein, the defining member of the HMG superfamily. This small, ~25 kDa protein functions as a transcription factor that bends DNA and assists other DNA-binding proteins to form their recognition complexes (16, 17) . HMGB1 consists of two tandem DNA binding domains, high mobility group box A and B, and a highly acidic C terminal tail composed of a string of aspartate and glutamate residues ( Figure 1 ). Both domains A and B consist of three α-helices that cooperatively wrap around DNA, approaching from the minor groove, in the DNA-HMG box complex. HMG boxes in HMGB1 bind to DNA in a structure-specific but sequence-independent manner, with greater binding affinity for nonlinear DNA such as bent, kinked, or unwound duplexes (18, 19) . HMGB1 as well as the A and B domains binds to platinated lesions on DNA with specificity for 1,2-intrastrand cross-links (20) , which account for about 90% of the cisplatin-DNA adducts formed in vivo (21, 22) . HMGB1 also has binding selectivity for interstrand cross-linked (ICLs) versus undamaged DNA, but not 1,3-intrastrand cross-links (23) . HMGB1 domain A binds with greater specificity to platinated DNA than does domain B. In full-length HMGB1, it is the A domain that mainly binds to platinated lesions, although domain B also plays a role in strengthening the interaction (24) .
An X-ray crystallographic analysis and binding assay revealed details of the interaction between HMGB1 domain A and DNA harboring a cisplatin 1,2-intrastrand d(GpG) cross-link ( Figure 2 ) (25) . A critical feature that dramatically enhances the binding preference of the domain for the platinated DNA is the occurrence of an intercalating residue, Phe37. The phenyl ring of Phe37 inserts into a hydrophobic notch formed in the minor groove across from the two platinum-modified guanine bases, and this stacking interaction significantly stabilizes the overall protein-DNA complexes and leads to an asymmetric positioning of the protein with respect to the platinum cross-link (24, 25) .
The sensitivity of the cells to cisplatin can be altered by changing the expression levels of HMGB1 and other HMG-domain proteins (26) (27) (28) . Moreover, in vitro repair assays reveal that HMGB1 impedes nucleotide excision repair (NER), the major mechanism by which platinated lesions are removed from DNA (29) (30) (31) . Taken together, these studies suggest that HMGB1 bound to cisplatinmodified DNA shields the platinated lesion from recognition by the repair proteins. A correlation between HMGB1 and cisplatin cytotoxicity, however, is not universally obtained. A cytotoxicity study revealed that the cisplatin sensitivity in genetically modified HMGB1 knockout mouse embryonic fibroblasts (MEFs) is not substantially different from that of the parental MEF call line (32) . The failure to correlate cell sensitivity to cisplatin with HMG box protein levels indicates either that there is no such correlation or that one or more variable factors among different cell lines alter the HMGB1-platinated DNA interaction. The present study was undertaken to test one possibility for the latter explanation.
HMGB1 domain A contains two cysteine residues, in positions 22 and 44, which can form a disulfide bond under mildly oxidizing conditions (33) . Previous work revealed that oxidation or modification of these cysteine thiols decreases the binding affinity of HMGB1 to various DNA probes, including a cisplatin-modified one (34) (35) (36) . Recently, the redox properties of HMGB1 domain A were investigated by NMR spectroscopy (37) . The calculated redox potential of domain A falls within the physiological intracellular redox potential range, which suggests that a significant fraction of HMGB1 will exist in the oxidized form within cells. It is therefore possible that the variability in cellular response to cisplatin as a function of HMG box proteins will reflect the redox state of the cells.
In this article, we describe the influence of redox state changes within the HMGB1 domain A protein on its binding to DNA containing a cisplatin 1,2-d(GpG) intrastrand cross-link. The binding properties of HMGB1 domain A and variants modified to prevent disulfide bond formation were investigated under different redox conditions using electrophoretic mobility shift assays (EMSAs) and hydroxyl radical footprinting. The detailed changes in the nature of the binding and their dependence upon redox conditions are discussed in the light of the previously reported crystal structure of HMGB1 domain A bound to platinated DNA probe under reducing conditions. Our results allow an assessment of the importance of the HMGB1 redox state for the efficacy of the anticancer action of cisplatin and other bifunctional platinum-based drugs. GGAGAGAAGATCCAGAGAGGAGAGG -3') were purchased from Intergrated DNA Technologies and purified by ion exchange HPLC as previously described (38) . Purified strands were platinated with cisplatin at the guanine residues bearing an asterisk, as previously described (38) , and undesired products were removed by HPLC. The cisplatin-modified strand, unmodified strand, and the complementary strand were characterized by ion exchange HPLC, S1-nuclease analysis, and flameless Pt atomic absorption spectroscopy. high binding specificity for cisplatin-modified DNA over unmodified DNA. Under reducing conditions, the K d value of the unmodified probe is more than 1000-fold greater than that of the cisplatin-modified probe having the same sequence ( Figure S1 , Supporting Information).
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Binding Affinity of Wild Type Domain
Site-Directed Mutagenesis of Cysteine Residues.
To examine the role of cysteine residues on the binding of HMGB1 domain A to platinated DNA, assays of singly or doubly mutated recombinant domain A proteins C22A, C44A, C44S, C22A/C44A, and C22S/C44S were carried out. There was no evidence of dimer formation by intermolecular disulfide bond formation involving two singly modified variants on non-reducing SDS-PAGE. Unlike wild type domain A, no variant displayed a significant difference in binding affinity for reducing versus non-reducing conditions ( Figures 4B, 4C ). This result was expected because these variants are unable to form the intramolecular disulfide bonds. All of these variants exhibited lower binding affinity compared to wild type domain A under reducing conditions (Table 1) .
Variants with serines replacing cysteines showed slightly higher binding affinity than those having alanines, presumably because of the more conservative nature of the replacement. Singly mutated variants have higher binding affinity than doubly mutated ones. The doubly mutated variant C22A/C44A
showed the lowest relative binding affinity, however, compared to that of fully oxidized wild type do- Disulfide bonds are the most common covalent linkages between protein side chains. Thioldisulfide interconversions can change important properties of proteins, including local/global conforma-tions and metal-binding affinity in a redox-dependent manner and thereby regulate many critical intracellular functions (42, 47, 48) . The stability of the disulfide bond under physiological conditions is highly sensitive to the redox potential of the cysteine/cystine redox pair, which is determined by the protein local environment.
HMGB1 domain A has two cysteine residues adjacent to each other in its tertiary structure (Figure 2) . The standard redox potential of the intramolecular disulfide bond of domain A is -237 ± 7 mV can explain the controversial results in previous attempts to establish a correlation between expression levels of HMGB1 and cisplatin cytotoxicity.
HMGB Proteins and High Toxicity of Cisplatin Toward Testicular Cancer.
Cisplatin is particularly effective against testicular cancer (2). After the structure-specific binding properties of HMG-domain proteins to platinated DNA and the repair-retarding capacity of HMGB1 were reported, HMGB proteins specific to testes were noted as elements that might participate in sensitizing testicular cancer toward cisplatin. Unlike HMGB1, which is expressed universally among mammalian cells, HMGB2, which has a similar sequence and structure as HMGB1, is over-expressed in testis cells (51) . An increase in the expression level of HMGB2 by transfection of an HMGB2 cDNA enhanced the cisplatin sensitivity of PC-14 cells (52) . Also, previous studies on testis-specific HMG (tsHMG), a murine HMG-domain protein, demonstrated that expression of the protein in the HeLa cells substantially sensitizes them to cisplatin (27) .
Recently, HMGB4, a new member of HMGB protein superfamily was discovered (53) . 
